Balance Sheet
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Telix Pharmaceuticals (TLX) Shares Outstanding (Weighted Average) (2023 - 2025)

Telix Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 3 years, most recently at $480.0 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 119.27% to $480.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $480.0 million through Dec 2025, up 119.27% year-over-year, with the annual reading at $480.0 million for FY2025, 15.93% up from the prior year.
  • Shares Outstanding (Weighted Average) was $480.0 million for Q4 2025 at Telix Pharmaceuticals, up from $218.9 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $480.0 million in Q4 2025 and troughed at $210.7 million in Q4 2023.
  • The 3-year median for Shares Outstanding (Weighted Average) is $218.9 million (2024), against an average of $303.2 million.
  • Year-over-year, Shares Outstanding (Weighted Average) grew 3.87% in 2024 and then soared 119.27% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $210.7 million in 2023, then grew by 3.87% to $218.9 million in 2024, then soared by 119.27% to $480.0 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Shares Outstanding (Weighted Average) are $480.0 million (Q4 2025), $218.9 million (Q4 2024), and $210.7 million (Q4 2023).